• Publications
  • Influence
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of patients with cardiovascular disease. However, recurrent ischemic event occurrence during dual antiplateletExpand
  • 1,032
  • 57
Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance
  • M. Cattaneo
  • Medicine
  • Arteriosclerosis, thrombosis, and vascular…
  • 1 November 2004
Aspirin and the thienopyridines ticlopidine and clopidogrel are antiplatelet agents that display good antithrombotic activity. In the past few years, the concept of aspirin resistance has beenExpand
  • 413
  • 24
  • PDF
Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH
Light transmission aggregometry (LTA) is the most common method used to assess platelet function. However, there is no universal standard for its performance. The Platelet Physiology Subcommittee ofExpand
  • 299
  • 24
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for
Factor V Leiden and factor II G20210A mutations are two frequent genetic risk factors involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprisingExpand
  • 344
  • 13
Hyperhomocysteinemia, atherosclerosis and thrombosis.
  • M. Cattaneo
  • Medicine
  • Thrombosis and haemostasis
  • 1 February 1999
High plasma levels of homocysteine are the results of the interplay between congenital and environmental factors. In the last two decades, a growing amount of interest has focused on mild-to-moderateExpand
  • 331
  • 12
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
  • M. Cattaneo
  • Medicine
  • Journal of thrombosis and haemostasis : JTH
  • 1 July 2007
Summary.  The definition ‘resistance to antiplatelet drugs’ should be limited to situations in which failure of the drug to hit its pharmacological target has been documented by specific laboratoryExpand
  • 176
  • 11
Platelet function analyzer (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function
Summary.  Background: Closure time (CT), measured by platelet function analyzer (PFA‐100®) device, is now available to the clinical laboratory as a possible alternative or supplement to the bleedingExpand
  • 350
  • 9
  • PDF
A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506).
Hyperhomocysteinemia is a frequent risk factor for deep-vein thrombosis. A common mutation (C677T) in the gene encoding for methylenetetrahydrofolate reductase (MTHFR) is responsible, in theExpand
  • 182
  • 9
  • PDF
New P2Y12 Inhibitors
A denosine diphosphate (ADP) plays a key role in the genesis of physiological platelet-rich hemostatic plugs and of pathological arterial thrombi.1 The transduction of the ADP signal involves itsExpand
  • 174
  • 9
Platelet P2 receptors: old and new targets for antithrombotic drugs
  • M. Cattaneo
  • Medicine
  • Expert review of cardiovascular therapy
  • 1 January 2007
Platelets possess three P2 receptors for adenine nucleotides: P2Y1 and P2Y12, which interact with ADP, and P2X1, which interacts with ATP. The interaction of adenine nucleotides with their plateletExpand
  • 86
  • 9